You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm's CFO said that the timing of revenue recognition on the Beacon carrier screening test prevented Fulgent from recording revenues from the tests in Q4.
The company recently demonstrated the potential of its PCR and NGS assays to diagnose infections in patients' prosthetic knees and hips.
The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.
The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
The researchers developed a qPCR test that analyzes microRNAs associated with ovarian cancer and plan to run a retrospective trial of the assay on biobanked samples.
The test is designed to detect and differentiate herpes simplex virus types 1 and 2, Treponema pallidum, and varicella-zoster virus.
Despite the initial high cost, the firm believes the assay's improved accuracy and sensitivity will sway clinical and payor interest.
GenomeDx will have exclusive rights to distribute the molecular tests in most of the US, while Pathnostics continues to perform the assays in-house.
Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.